Literature DB >> 11420888

Effect of vigabatrin and gabapentin on phynytoin pharmacokinetics in the dog.

K M Matar1, P J Nicholls, A Tekle, S A Bawazir, M I al-Hassan.   

Abstract

The study was aimed at investigating whether or not the kinetics of intravenously administered phenytoin (PT) was altered by oral administration of vigabatrin (VGB) or gabapentin (GBP). A group of five beagle dogs were given a daily dose of PT (12 mg/kg, i.v.) for a period of 1 week. On day 8, plasma samples were serially collected over 24 hr. after administration of the PT dose. PT administration was continued with oral supplementary dose of VGB (60 mg/kg) for another week and then plasma samples were collected for analysis of PT levels. The same protocol was followed for the PT (12 mg/kg, i.v.)-GBP (300 mg caps., p.o.) study on a separate group (n = 5) of dogs. Orally administered GBP did not significantly alter the pharmacokinetic parameters of parental PT. VGB, however markedly changed the drug's kinetics as evidenced by a 31% (P = 0.015) reduction in total body clearance (CL) and increase of over 45% in half-life (t1/2), (P = 0.013) and area under the plasma PT concentration-time curve (AUC), (P = 0.044). GBP does not appear to have any pharmacokinetic interaction with PT, while coadministration of VGB and PT results in marked reduction in systemic clearance of the latter in the dog.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 11420888     DOI: 10.1007/BF03192312

Source DB:  PubMed          Journal:  Eur J Drug Metab Pharmacokinet        ISSN: 0378-7966            Impact factor:   2.441


  15 in total

Review 1.  A mechanistic approach to antiepileptic drug interactions.

Authors:  G D Anderson
Journal:  Ann Pharmacother       Date:  1998-05       Impact factor: 3.154

2.  Interaction between vigabatrin and phenytoin.

Authors:  E M Rimmer; A Richens
Journal:  Br J Clin Pharmacol       Date:  1989       Impact factor: 4.335

3.  Vigabatrin for refractory complex partial seizures: multicenter single-blind study with long-term follow-up.

Authors:  T R Browne; R H Mattson; J K Penry; D B Smith; D M Treiman; B J Wilder; E Ben-Menachem; M J Napoliello; K M Sherry; G K Szabo
Journal:  Neurology       Date:  1987-02       Impact factor: 9.910

Review 4.  Pharmacokinetic interactions between antiepileptic drugs. Clinical considerations.

Authors:  R Riva; F Albani; M Contin; A Baruzzi
Journal:  Clin Pharmacokinet       Date:  1996-12       Impact factor: 6.447

5.  Inhibition of the enzyme, GABA-aminotransferase in human platelets by vigabatrin, a potential antiepileptic drug.

Authors:  E Rimmer; G Kongola; A Richens
Journal:  Br J Clin Pharmacol       Date:  1988-02       Impact factor: 4.335

Review 6.  Pharmacology of vigabatrin.

Authors:  A Sabers; L Gram
Journal:  Pharmacol Toxicol       Date:  1992-04

Review 7.  Pharmacology and clinical pharmacology of vigabatrin.

Authors:  A Richens
Journal:  J Child Neurol       Date:  1991       Impact factor: 1.987

8.  The effect of gabapentin on brain gamma-aminobutyric acid in patients with epilepsy.

Authors:  O A Petroff; D L Rothman; K L Behar; D Lamoureux; R H Mattson
Journal:  Ann Neurol       Date:  1996-01       Impact factor: 10.422

Review 9.  Gabapentin: a new agent for the management of epilepsy.

Authors:  C O Andrews; J H Fischer
Journal:  Ann Pharmacother       Date:  1994-10       Impact factor: 3.154

10.  Isolation of human hepatic microsomes and their inhibition by cimetidine and ranitidine.

Authors:  H P Hoensch; H Hutzel; W Kirch; E E Ohnhaus
Journal:  Eur J Clin Pharmacol       Date:  1985       Impact factor: 2.953

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.